Skip to main content
Erschienen in: Osteoporosis International 5/2016

11.12.2015 | Original Article

Optimal age of commencing and discontinuing thiazide therapy to protect against fractures

verfasst von: C. Kruse, P. Eiken, P. Vestergaard

Erschienen in: Osteoporosis International | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

A study of national Danish patient data with regard to thiazide diuretics vs. non-treatment. We find that after age 83 years, thiazides increase the 10-year risk of major fractures. We also find that thiazides can be stopped after 63 years old to possibly protect against fracture occurrence.

Introduction

The purpose of this study was to retrospectively examine the optimal age for commencing and discontinuing thiazide therapy to protect from osteoporotic fractures.

Methods

A population-based, retrospective matched cohort study was done using national data of 2.93 million Danish subjects. Ten-year crude and adjusted age-grouped hazard ratios (HRs) of fracture occurrence were stratified by age of commencing thiazides compared to non-exposure. Separate analyses were done on Anatomical Therapeutic Chemical Classification System (ATC) codes C03AA and C03AA + C03AB compiled. Ten-year crude HRs of fracture occurrence for discontinuing vs. continuing thiazides were estimated and stratified by age for the two groups.

Results

For C03AB alone (97.1 % of thiazide prescriptions), adjusted 10-year HRs of fracture occurrence were significantly increased for thiazide commencement after age 83 years and comparable to non-exposure for commencement between ages 50 and 83 years. For C03AA + C03AB, 10-year adjusted HRs of fracture occurrence were significantly increased from ages 73 years and upwards. Crude 10-year HRs of fracture occurrence were significantly decreased for discontinuing vs. continuing thiazides at or after age 63 years for C03AB and age 77 years for C03AA + C03AB.

Conclusions

No significantly protective effect of thiazides was found on fracture occurrence compared to non-users, but evidence that thiazides increase the 10-year adjusted HR risk of fractures if prescribed after the age of 83 years for C03AB and 73 years for C03AA + C03AB. Discontinuing thiazides at or after age 63 years for C03AB or 77 years for C03AA & C03AB significantly decreases the 10-year risk of fractures compared to continuing thiazides. Further prospective studies are warranted.
Literatur
1.
Zurück zum Zitat Wasnich RD, Ross PD, Heilbrun LK, Vogel JM, Yano K, Benfante RJ (1986) Differential effects of thiazide and estrogen upon bone mineral content and fracture prevalence. Obstet Gynecol 67(4):457–462PubMed Wasnich RD, Ross PD, Heilbrun LK, Vogel JM, Yano K, Benfante RJ (1986) Differential effects of thiazide and estrogen upon bone mineral content and fracture prevalence. Obstet Gynecol 67(4):457–462PubMed
2.
Zurück zum Zitat Felson DT, Sloutskis D, Anderson JJ, Anthony JM, Kiel DP (1991) Thiazide diuretics and the risk of hip fracture. Results from the Framingham study. JAMA 265(3):370–373CrossRefPubMed Felson DT, Sloutskis D, Anderson JJ, Anthony JM, Kiel DP (1991) Thiazide diuretics and the risk of hip fracture. Results from the Framingham study. JAMA 265(3):370–373CrossRefPubMed
3.
Zurück zum Zitat Herings RM, Stricker BH, De Boer A, Bakker A, Sturmans F, Stergachis A (1996) Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 49(1):115–119CrossRefPubMed Herings RM, Stricker BH, De Boer A, Bakker A, Sturmans F, Stergachis A (1996) Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 49(1):115–119CrossRefPubMed
4.
Zurück zum Zitat Kelsey JL, Prill MM, Keegan TH et al (2005) Reducing the risk for distal forearm fracture: preserve bone mass, slow down, and don’t fall! Osteoporos Int 16(6):681–690CrossRefPubMed Kelsey JL, Prill MM, Keegan TH et al (2005) Reducing the risk for distal forearm fracture: preserve bone mass, slow down, and don’t fall! Osteoporos Int 16(6):681–690CrossRefPubMed
5.
Zurück zum Zitat Ray WA, Griffin MR, Downey W, Melton LJ (1989) Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1(8640):687–690CrossRefPubMed Ray WA, Griffin MR, Downey W, Melton LJ (1989) Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1(8640):687–690CrossRefPubMed
6.
Zurück zum Zitat Rejnmark L, Vestergaard P, Mosekilde L (2005) Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 76(3):167–175CrossRefPubMed Rejnmark L, Vestergaard P, Mosekilde L (2005) Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 76(3):167–175CrossRefPubMed
7.
Zurück zum Zitat Song HJ, Lee J, Kim YJ et al (2012) β1 selectivity of β-blockers and reduced risk of fractures in elderly hypertension patients. Bone 51(6):1008–1015CrossRefPubMed Song HJ, Lee J, Kim YJ et al (2012) β1 selectivity of β-blockers and reduced risk of fractures in elderly hypertension patients. Bone 51(6):1008–1015CrossRefPubMed
8.
Zurück zum Zitat Aung K, Htay T (2011) Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev. (10):CD005185 Aung K, Htay T (2011) Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev. (10):CD005185
9.
Zurück zum Zitat Feskanich D, Willett WC, Stampfer MJ, Colditz GA (1997) A prospective study of thiazide use and fractures in women. Osteoporos Int 7(1):79–84CrossRefPubMed Feskanich D, Willett WC, Stampfer MJ, Colditz GA (1997) A prospective study of thiazide use and fractures in women. Osteoporos Int 7(1):79–84CrossRefPubMed
10.
Zurück zum Zitat Lacroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 133(7):516–526CrossRefPubMed Lacroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 133(7):516–526CrossRefPubMed
11.
Zurück zum Zitat Lacroix AZ, Wienpahl J, White LR et al (1990) Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 322(5):286–290CrossRefPubMed Lacroix AZ, Wienpahl J, White LR et al (1990) Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 322(5):286–290CrossRefPubMed
12.
Zurück zum Zitat Hoorn EJ, Rivadeneira F, Van Meurs JB et al (2011) Mild hyponatremia as a risk factor for fractures: the Rotterdam study. J Bone Miner Res 26(8):1822–1828CrossRefPubMed Hoorn EJ, Rivadeneira F, Van Meurs JB et al (2011) Mild hyponatremia as a risk factor for fractures: the Rotterdam study. J Bone Miner Res 26(8):1822–1828CrossRefPubMed
14.
Zurück zum Zitat Schoofs MW, Van der Klift M, Hofman A et al (2003) Thiazide diuretics and the risk for hip fracture. Ann Intern Med 139(6):476–482CrossRefPubMed Schoofs MW, Van der Klift M, Hofman A et al (2003) Thiazide diuretics and the risk for hip fracture. Ann Intern Med 139(6):476–482CrossRefPubMed
15.
Zurück zum Zitat Schlienger RG, Kraenzlin ME, Jick SS, Meier CR (2004) Use of beta-blockers and risk of fractures. JAMA 292(11):1326–1332CrossRefPubMed Schlienger RG, Kraenzlin ME, Jick SS, Meier CR (2004) Use of beta-blockers and risk of fractures. JAMA 292(11):1326–1332CrossRefPubMed
16.
Zurück zum Zitat Cauley JA, Cummings SR, Seeley DG et al (1993) Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The study of osteoporotic fractures research group. Ann Intern Med 118(9):666–673CrossRefPubMed Cauley JA, Cummings SR, Seeley DG et al (1993) Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The study of osteoporotic fractures research group. Ann Intern Med 118(9):666–673CrossRefPubMed
17.
Zurück zum Zitat Kruse C, Eiken P, Vestergaard P (2015) Continuous and long-term treatment is more important than dosage for the protective effect of thiazide use on bone metabolism and fracture risk. J Intern Med Kruse C, Eiken P, Vestergaard P (2015) Continuous and long-term treatment is more important than dosage for the protective effect of thiazide use on bone metabolism and fracture risk. J Intern Med
18.
Zurück zum Zitat Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L (2001) Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med 250(2):144–153CrossRefPubMed Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L (2001) Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med 250(2):144–153CrossRefPubMed
19.
Zurück zum Zitat Legroux-gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B (2004) Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine 71(1):51–55CrossRefPubMed Legroux-gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B (2004) Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine 71(1):51–55CrossRefPubMed
20.
Zurück zum Zitat Hansson T, Roos B (1986) Age changes in the bone mineral of the lumbar spine in normal women. Calcif Tissue Int 38(5):249–251CrossRefPubMed Hansson T, Roos B (1986) Age changes in the bone mineral of the lumbar spine in normal women. Calcif Tissue Int 38(5):249–251CrossRefPubMed
21.
Zurück zum Zitat Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ (1981) Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest 67(2):328–335CrossRefPubMedPubMedCentral Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ (1981) Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest 67(2):328–335CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Riggs BL, Wahner HW, Seeman E et al (1982) Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 70(4):716–723CrossRefPubMedPubMedCentral Riggs BL, Wahner HW, Seeman E et al (1982) Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 70(4):716–723CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Nordin BE, Need AG, Morris HA, Horowitz M, Robertson WG (1991) Evidence for a renal calcium leak in postmenopausal women. J Clin Endocrinol Metab 72(2):401–407CrossRefPubMed Nordin BE, Need AG, Morris HA, Horowitz M, Robertson WG (1991) Evidence for a renal calcium leak in postmenopausal women. J Clin Endocrinol Metab 72(2):401–407CrossRefPubMed
24.
Zurück zum Zitat Adami S, Gatti D, Bertoldo F et al (1992) The effects of menopause and estrogen replacement therapy on the renal handling of calcium. Osteoporos Int 2(4):180–185CrossRefPubMed Adami S, Gatti D, Bertoldo F et al (1992) The effects of menopause and estrogen replacement therapy on the renal handling of calcium. Osteoporos Int 2(4):180–185CrossRefPubMed
25.
Zurück zum Zitat Selby PL, Peacock M, Barkworth SA, Brown WB, Taylor GA (1985) Early effects of ethinyloestradiol and norethisterone treatment in post-menopausal women on bone resorption and calcium regulating hormones. Clin Sci 69(3):265–271CrossRefPubMed Selby PL, Peacock M, Barkworth SA, Brown WB, Taylor GA (1985) Early effects of ethinyloestradiol and norethisterone treatment in post-menopausal women on bone resorption and calcium regulating hormones. Clin Sci 69(3):265–271CrossRefPubMed
26.
Zurück zum Zitat Olmos JM, Hernández JL, Martínez J et al (2010) Bone turnover markers and bone mineral density in hypertensive postmenopausal women on treatment. Maturitas 65(4):396–402CrossRefPubMed Olmos JM, Hernández JL, Martínez J et al (2010) Bone turnover markers and bone mineral density in hypertensive postmenopausal women on treatment. Maturitas 65(4):396–402CrossRefPubMed
27.
Zurück zum Zitat Assimos DG (2003) Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. J Urol 190(2):570–571 Assimos DG (2003) Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. J Urol 190(2):570–571
28.
Zurück zum Zitat Bolland MJ, Ames RW, Horne AM, Orr-walker BJ, Gamble GD, Reid IR (2007) The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 18(4):479–486CrossRefPubMed Bolland MJ, Ames RW, Horne AM, Orr-walker BJ, Gamble GD, Reid IR (2007) The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 18(4):479–486CrossRefPubMed
29.
Zurück zum Zitat Reid IR, Ames RW, Orr-walker BJ et al (2000) Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 109(5):362–370CrossRefPubMed Reid IR, Ames RW, Orr-walker BJ et al (2000) Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 109(5):362–370CrossRefPubMed
30.
Zurück zum Zitat Ikeda C, Saito Y, Sukigara S et al (2011) Effects of low-dose hydrochlorothiazide on urolithiasis and bone metabolism in severely disabled individuals: a pilot study. Brain Dev 33(5):400–405CrossRefPubMed Ikeda C, Saito Y, Sukigara S et al (2011) Effects of low-dose hydrochlorothiazide on urolithiasis and bone metabolism in severely disabled individuals: a pilot study. Brain Dev 33(5):400–405CrossRefPubMed
31.
Zurück zum Zitat Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD (1995) Landspatientregisteret. Evaluering af datakvaliteten. Danish Med J 157(26):3741–3745 Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD (1995) Landspatientregisteret. Evaluering af datakvaliteten. Danish Med J 157(26):3741–3745
32.
Zurück zum Zitat Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 156(1):1–10CrossRefPubMed Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 156(1):1–10CrossRefPubMed
Metadaten
Titel
Optimal age of commencing and discontinuing thiazide therapy to protect against fractures
verfasst von
C. Kruse
P. Eiken
P. Vestergaard
Publikationsdatum
11.12.2015
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 5/2016
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3451-0

Weitere Artikel der Ausgabe 5/2016

Osteoporosis International 5/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.